WallStSmart
GALT

Galectin Therapeutics Inc

NASDAQ: GALT · HEALTHCARE · BIOTECHNOLOGY

$3.02
-0.98% today

Updated 2026-11-16

Market cap
$307.59M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.43
Dividend yield
—
52W range
$2 – $7
Volume
0.2M

WallStSmart proprietary scores

19
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
4.5
Quality
C
3.0
Profitability
D
5.0
Valuation
C+
3/9
Piotroski F-Score
Weak
-34.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →253 stocks currently score above 75

Price targets

Analyst target
$11.00
+264.24%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
+ Debt/equity -1.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -34.27 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.44M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-38.78M$-41.07M$-47.05M$-30.84M$-9.11M
EPS————$-0.43
Free cash flow$-31.06M$-32.97M$-41.77M$-23.88M$-2.44M
Profit margin—————

Recent insider activity

DateInsiderTypeSharesPrice
2026-07-31UIHLEIN, RICHARD EBuy31,825,235$3.00
2026-07-31UIHLEIN, RICHARD EBuy2,550,932$4.05
2026-07-14JAMIL, KHURRAMSale16,250—

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
GALT$307.59M194.33.05.04.5—Avoid
LLY$1.27T749.310.05.06.0—Strong Buy
JNJ$682.52B544.78.53.75.5—Buy
ABBV$520.47B776.79.04.05.0-87.62%Strong Buy
UNH$363.01B626.76.04.75.5-24.67%Buy
MRK$362.27B423.36.52.05.0-73.98%Hold

Smart narrative

Galectin Therapeutics Inc trades at $3.02. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -34.27, it sits in the distress.

Frequently asked questions

What is Galectin Therapeutics Inc's stock price?

Galectin Therapeutics Inc (GALT) trades at $3.02.

Is Galectin Therapeutics Inc overvalued?

Galectin Therapeutics Inc carries a Smart Value Score of 19/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Galectin Therapeutics Inc (GALT)?

The 12-month analyst consensus target is $11.00, about 264.2% above the current $3.02. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Galectin Therapeutics Inc's Altman Z-Score is -34.27, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio—
ROE-3,728.00%
Beta0.50
50D MA$3.65
200D MA$3.21
Shares out0.10B
Float0.05B
Short ratio—
Avg volume0.2M

Performance

1 week-8.12%
1 month-2.43%
3 months-13.29%
YTD-12.98%
1 year-27.45%
3 years—
5 years—